OPTICAL COHERENCE TOMOGRAPHY BIOMARKERS FOR REDUCTION OF DRUSENOID PIGMENT EPITHELIUM DETACHMENT

Background: To evaluate long-term visual/anatomic outcome after anti-vascular endothelial growth factor (anti-VEGF) therapy in patients with fovea-involving fibrovascular pigment epithelium detachment (PED) presenting with choroidal neovascularization (CNV) on optical coherence tomography angiography (OCTA). Methods: Patients with fibrovascular PED or subretinal CNV confirmed by OCTA who were treated by a relaxed treat-and-extend regimen for 2 years were retrospectively reviewed. The best-corrected visual acuity (BCVA) and central subfield retinal thickness (CST) before and after anti-VEGF injection were analyzed. Furthermore, changes in photoreceptor layer (PRL) thickness and outer retinal bands in the fovea after injection were evaluated. Results: A total of 31 eyes with fibrovascular PED and 24 eyes with subretinal CNV were included. Following a relaxed treat-and-extend regimen with anti-VEGF agents, BCVA and CST were improved, and the PRL thickness was decreased significantly. There were no differences in BCVA, CST, changes in PRL thickness, or the status of outer retinal bands between the groups. However, the difference in the amount of decrease in PRL thickness between the two groups was increased at 2 years, and the slope tended to be steeper in the subretinal CNV group. Conclusions: Exudative age-related macular degeneration (AMD) with fibrovascular PED or subretinal CNV showed good visual/anatomic outcomes after anti-VEGF treatment, regardless of the CNV type. By 2 years, fibrovascular PED did not have an additional protective effect on the outer retina, compared with subretinal CNV over 2 years. Further follow-up study might be needed to conclude that fibrovascular PED has a protective effect on the surrounding photoreceptor area.

Download Full-text

Management of pigment epithelium detachment using Spectral Domain Optical Coherence Tomography.

10.35841/clinical-ophthalmology.3.1.121-124 ◽

2018 ◽

Vol 03 (01) ◽

Author(s):

Rebecca Rolf ◽

Florence Coscas ◽

Gabriel Coscas ◽

Salomon Yves Cohen ◽

Eric H Souied

Keyword(s):

Optical Coherence Tomography ◽

Pigment Epithelium ◽

Spectral Domain ◽

Optical Coherence ◽

Pigment Epithelium Detachment

Download Full-text

OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY OF FLAT IRREGULAR PIGMENT EPITHELIUM DETACHMENT IN CHRONIC CENTRAL SEROUS CHORIORETINOPATHY

Retina ◽

10.1097/iae.0000000000001580 ◽

2018 ◽

Vol 38 (3) ◽

pp. 629-638 ◽

Cited By ~ 41

Author(s):

Elodie Bousquet ◽

Sophie Bonnin ◽

Sarah Mrejen ◽

Valérie Krivosic ◽

Ramin Tadayoni ◽

...

Keyword(s):

Optical Coherence Tomography ◽

Central Serous Chorioretinopathy ◽

Optical Coherence Tomography Angiography ◽

Pigment Epithelium ◽

Optical Coherence ◽

Chronic Central Serous Chorioretinopathy ◽

Pigment Epithelium Detachment

Download Full-text

Small dome-shaped pigment epithelium detachment in polypoidal choroidal vasculopathy: an under-recognized sign of polypoidal lesions on optical coherence tomography?

Eye ◽

10.1038/s41433-020-01390-0 ◽

2021 ◽

Author(s):

Yuwei Wang ◽

Qiyu Bo ◽

Huixun Jia ◽

Mengsha Sun ◽

Yang Yu ◽

...

Keyword(s):

Optical Coherence Tomography ◽

Polypoidal Choroidal Vasculopathy ◽

Pigment Epithelium ◽

Optical Coherence ◽

Pigment Epithelium Detachment ◽

Choroidal Vasculopathy

Download Full-text

Comparison of the therapy effect of aflibercept and ranibizumab in patients with neovascular retinal pigment epithelium detachment identified by fluorescence angiography and optical coherence tomography angiography

10.21203/rs.2.11299/v1 ◽

2019 ◽

Author(s):

Anne Ruebsam ◽

Pohlmann Dominika ◽

Dietrich-Ntoukas Tina ◽

Müller Bert ◽

Antonia M Joussen ◽

...

Keyword(s):

Optical Coherence Tomography ◽

Optical Coherence Tomography Angiography ◽

Pigment Epithelium ◽

Retinal Pigment ◽

Fluorescence Angiography ◽

Optical Coherence ◽

Pigment Epithelium Detachment ◽

Therapy Effect ◽

Cnv Detection ◽

Therapy Switch

Abstract Background To report on the current methods for choroidal neovascularization (CNV) detection and the clinical outcome of intravitreal therapies in patients with neovascular pigment epithelium detachment (PED). Methods Retrospective, interventional cohort study on 77 eyes of 59 patients. Inclusion criteria were a neovascular PED, identified by fluorescence angiography (FA) or/and optical coherence tomography angiography (OCTA) treated with aflibercept (16 eyes) or ranibizumab monotherapy (36 eyes) or with at least three injections of ranibizumab, with a therapy switch to aflibercept in case of persistent fluid (25 eyes). The therapy regimen was a pro re nata (PRN) scheme with an upload phase of three monthly injections. Outcome measures were sensitivity of CNV detection and evaluation of CNV activity at baseline on FA compared to OCTA, the change in highest retinal prominence (HRP) and PED size, assessed by spectral - domain OCT (SD-OCT), and the change in best-corrected visual acuity (BCVA) three months after therapy initiation in the monotherapy groups or after the switch. Results Sensitivity of CNV detection was slightly superior for FA (0.786) compared to OCTA (0.706), whereas CNV activity evaluation was superior on OCTA. HRP significantly decreased after aflibercept (p<0.001) or ranibizumab monotherapy (p<0.001), and after therapy switch to aflibercept (p<0.001) in ranibizumab refractory patients. Corresponding BCVA improved in these groups, but without statistical significance (p=0.46; p = 0.11; p=0.19). PED size significantly decreased after aflibercept monotherapy (p=0.001) or after therapy switch to aflibercept (p<0.001), but not after ranibizumab. Conclusions The combination of FA and OCTA offers significantly improved visualisation, quantification, and predictability of CNV activity in neovascular PED. Aflibercept and ranibizumab are effective treatment options for neovascular AMD with PED, with a stronger effect of aflibercept on the PED itself. Furthermore, aflibercept appears to be a valuable tool for the management of patients unresponsive to ranibizumab.

Download Full-text